Dr. Reddy's Laboratories Ltd. (RDY - Free Report) reported first-quarter fiscal 2020 earnings of 58 cents per share, up from 40 cents in the year-ago quarter, per American Depositary Share (ADS).
Moreover, revenues increased 3% year over year to $558 million.
Year to date, shares of the company have increased 0.9% against the industry’s decline of 4.4%.
Quarter in Detail
Dr. Reddy’s reported revenues under three segments — Global Generics, Pharmaceutical Services & Active Ingredients (“PSAI”), and Proprietary Products and Others.
Global Generics revenues were INR33billion ($478.8 million), up 8% year over year in the fiscal first quarter. Growth was led by contributions from emerging markets and India, primarily owing to volume gains and product launches.
PSAI revenues were INR4.5 billion ($65.3 million), down 16% from the year-ago quarter.
Revenues at the Proprietary Products segment came in at INR281 million ($4.1 million), down 61%.
Research and development expenses were down 13% year over year to $52 million.
Selling, general and administrative expenses were $175 million, flat year over year.
As of Jun 30, 2019, Dr. Reddy’s had 107 generic filings (104 abbreviated New Drug Applications [ANDAs] and three new drug applications) pending FDA approval. Of these 104 ANDAs, 58 were Para IV filings and 34 have first-to-file status.
Our Take
In first-quarter fiscal 2020, Dr. Reddy’s top and bottom lines registered year-over-year growth. This was supported by significant growth in emerging markets and India, pickup in product launches, and improvements in cost structure.
However, the company expects to experience price erosion in the North America generics market.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Dr. Reddy's Laboratories Ltd. (RDY - Free Report) reported first-quarter fiscal 2020 earnings of 58 cents per share, up from 40 cents in the year-ago quarter, per American Depositary Share (ADS).
Moreover, revenues increased 3% year over year to $558 million.
Year to date, shares of the company have increased 0.9% against the industry’s decline of 4.4%.
Quarter in Detail
Dr. Reddy’s reported revenues under three segments — Global Generics, Pharmaceutical Services & Active Ingredients (“PSAI”), and Proprietary Products and Others.
Global Generics revenues were INR33billion ($478.8 million), up 8% year over year in the fiscal first quarter. Growth was led by contributions from emerging markets and India, primarily owing to volume gains and product launches.
PSAI revenues were INR4.5 billion ($65.3 million), down 16% from the year-ago quarter.
Revenues at the Proprietary Products segment came in at INR281 million ($4.1 million), down 61%.
Research and development expenses were down 13% year over year to $52 million.
Selling, general and administrative expenses were $175 million, flat year over year.
As of Jun 30, 2019, Dr. Reddy’s had 107 generic filings (104 abbreviated New Drug Applications [ANDAs] and three new drug applications) pending FDA approval. Of these 104 ANDAs, 58 were Para IV filings and 34 have first-to-file status.
Our Take
In first-quarter fiscal 2020, Dr. Reddy’s top and bottom lines registered year-over-year growth. This was supported by significant growth in emerging markets and India, pickup in product launches, and improvements in cost structure.
However, the company expects to experience price erosion in the North America generics market.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on RDY - FREE
Get the latest research report on NVS - FREE
Get the latest research report on RHHBY - FREE
Get the latest research report on ABBV - FREE